Januszewski, Andrzej S.
Chen, David
Scott, Russell S.
O’Connell, Rachel L.
Aryal, Nanda R.
Sullivan, David R.
Watts, Gerald F.
Taskinen, Marja-Riitta
Barter, Philip J.
Best, James D.
Simes, R. John
Keech, Anthony C.
Jenkins, Alicia J.
Funding for this research was provided by:
Laboratoires Fournier SA
Solvay Pharmaceuticals
Abbott Pharmaceuticals
Mylan
National Health and Medical Research Council of Australia
Sydney Medical School Foundation
Article History
Received: 11 February 2021
Accepted: 26 August 2021
First Online: 21 September 2021
Competing interests
: Some members of the writing committee (AJJ, JDB, PJB, DRS, and ACK) have had the costs of participating in scientific meetings and/or contributing to advisory boards or doing other research reimbursed by the pharmaceutical industry. ACK was a listed applicant on a patent application in relation to findings about fenofibrate and retinopathy, and reports grants from Abbott and Mylan as well as honoraria from Amgen, AstraZeneca, Pfizer, Sanofi, and Novartis. DRS reports grants and honoraria from Abbott and Mylan, and honoraria from Amgen, AstraZeneca and Pfizer. PJB reports honoraria from Amgen, AstraZeneca, Kowa, MSD and Pfizer, and AJJ reports rants from Abbott, Mylan. All other authors declare no competing interests.